A Phase 3 interventional study of rituximab [MabThera/Rituxan] and tocilizumab [RoActemra/Actemra] in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 83 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-09-07.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies testing tocilizumab in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, none of them phase 3. tocilizumab · Arthritis, Rheumatoid.
Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, this one is the 15th largest by enrollment, is one of 14 that started in 2011, is one of 65 in phase 3, and was the 51st registered.
3,337 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
Browse Arthritis, Rheumatoid studies →5 of the 110 studies testing tocilizumab in Arthritis, Rheumatoid are open now, in 12 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in United States, Australia, Brazil and 7 more countries
Ages 18+
Marie Hudson, MD · Sites in Canada
Ages 18+
Reade Rheumatology Research Institute · Sites in Netherlands
Ages 18+
Chinese SLE Treatment And Research Group · Sites in China
Ages 18–80
By country, each count listing its studies:
tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 65 · Phase 4 32
First in 2001; this study’s year is marked. 14 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 519 is above the median of 96 across 2,224 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 97 across the 110 interventional studies. Of the 98 that completed or were terminated, 66 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
88 of 110 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche: 2 open now, 2 under way, none of them phase 3. Of 214 finished, 139 (65%) have results posted.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 25th largest by enrollment of the 141 interventional ones that give a count, is one of 25 that started in 2011, is one of 85 in phase 3, and was the 104th registered.
Hoffmann-La Roche’s Arthritis, Rheumatoid studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, from their registry updates:
Among Hoffmann-La Roche’s 219 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This open-label, multi-center, two-arm, uncontrolled and non-randomized study will evaluate the efficacy and safety of RoActemra/Actemra (tocilizumab) in patients with rheumatoid arthritis. Patients will receive 8 mg/kg RoActemra/Actemra intravenously every 4 weeks for 12 weeks and - if adequately responded - for further 12 weeks. Patients, who show an inadequate clinical response after the first 12 weeks to RoActemra/Actemra, will receive 1 g MabThera/Rituxan (rituximab) intravenously at Week 16 and 18. The anticipated time of study treatment is 32 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: tocilizumab [RoActemra/Actemra]
Drug: rituximab [MabThera/Rituxan] · Drug: tocilizumab [RoActemra/Actemra]
Drug page: Rituximab
1 g intravenously at Week 16 and 18
Drug page: Tocilizumab
8 mg/kg intravenously every 4 weeks for 12 weeks.
Drug page: Tocilizumab
8 mg/kg intravenously every 4 weeks from Week 16 to Week 28
Percentage of Participants Achieving Remission at Week 16 According to DAS28
The DAS28 was calculated as \[0.28 times (x) the square root of number of swollen joints\] plus (+) \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of erythrocyte sedimentation rate (ESR)\] + \[0.014 x Visual Analog Scale (VAS) patient global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity. Remission was defined as a DAS28 score \<2.6 at the assessment visit.
Time frame: Week 16
Percentage of Participants Achieving Remission According to DAS28 at Weeks 4, 8, and 12
The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x VAS patient global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity. Remission was defined as a DAS28 score \<2.6 at the assessment visit.
Time frame: Weeks 4, 8, and 12
Percentage of Participants Achieving Remission According to DAS28 at Weeks 16, 20, 24, and 28 Among Participants Treated With 8 Courses of Tocilizumab
The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x VAS patient global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity. Remission was defined as a DAS28 score \<2.6 at the assessment visit.
Time frame: Weeks 16, 20, 24, and 28
Percentage of Participants Achieving Remission According to DAS28 at Week 32 Among Participants Treated With 8 Courses of Tocilizumab
The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x VAS patient global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity. Remission was defined as a DAS28 score \<2.6 at the assessment visit.
Time frame: Week 32
Percentage of Participants Achieving Remission According to DAS28 at Week 32 Among Nonresponding Participants Treated With Rituximab
The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x VAS patient global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity. Remission was defined as a DAS28 score \<2.6 at the assessment visit.
Time frame: Week 32
Percentage of Participants Achieving Low Disease Activity Score (LDAS) According to DAS28
The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x the patient global assessment of disease activity using a VAS\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity. LDAS was defined as a DAS28 score \<3.2 at the assessment visit.
Time frame: Week 16
Percentage of Participants Achieving LDAS According to DAS28 Among Among Nonresponding Participants Treated With Rituximab
The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x the patient global assessment of disease activity using a VAS\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity. LDAS was defined as a DAS28 score \<3.2 at the assessment visit.
Time frame: Week 32
Percentage of Participants Achieving a Clinically Relevant Reduction From Baseline in DAS28 at Week 16
The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x VAS patient global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity. Reductions \>1.2 points from Baseline to the assessment visit were considered clinically relevant.
Time frame: Baseline and Week 16
Percentage of Participants Achieving a Clinically Relevant Reduction From Baseline in DAS28 at Weeks 4, 8, and 12
The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x VAS patient global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity. Reductions \>1.2 points from Baseline to the assessment visit were considered clinically relevant.
Time frame: Baseline and Weeks 4, 8, and 12
Percentage of Participants Achieving a Clinically Relevant Reduction in DAS28 From Week 16 to Week 32 Among Nonresponding Participants Treated With Rituximab
The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x VAS patient global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity. Reductions \>1.2 points from the reference visit (Week 16) to the assessment visit were considered clinically relevant.
Time frame: Weeks 16 and 32
DAS28 Scores During and After Treatment
The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x VAS patient global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity.
Time frame: Baseline and Weeks 4, 8, 12, 16
DAS28 Scores During and After Treatment Among Participants Treated With 8 Courses of Tocilizumab
The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x VAS patient global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity.
Time frame: Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, and 32
DAS28 Scores During and After Treatment Among Nonresponding Participants Treated With Rituximab
The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x VAS patient global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity.
Time frame: Baseline and Weeks 4, 8, 12, 16, 24, and 32
DAS28 Scores During Safety Follow-Up Among Nonresponding Participants Treated With Rituximab
The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x VAS patient global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity.
Time frame: Weeks 40, 48, 56, and 66
Percentage of Participants Achieving a Response According to European League Against Rheumatism (EULAR) Criteria at Weeks 4, 8, 12 and 16
Response was determined using EULAR criteria based upon DAS28 absolute scores at the assessment visit and the DAS28 reduction from Baseline. Participants with a score ≤3.2 and reduction of \>1.2 points were assessed as having a 'good' response. Participants with a score \>3.2 with reduction of \>1.2 points, or a score ≤5.1 with reduction of \>0.6 to ≤1.2 points, were assessed as having a 'moderate' response. Participants with a score \>5.1 with reduction of \>0.6 to ≤1.2 points, or any score with reduction ≤0.6 points, were assessed as nonresponders with response recorded as 'none.'
Time frame: Baseline and Weeks 4, 8, 12, and 16
Percentage of Participants Achieving a Response According to EULAR Criteria at Week 32 Compared to Week 16 Among Nonresponding Participants Treated With Rituximab
Response was determined using EULAR criteria based upon DAS28 absolute scores at the assessment visit and the DAS28 reduction from the reference visit (Week 16). Participants with a score ≤3.2 and reduction of \>1.2 points were assessed as having a 'good' response. Participants with a score \>3.2 with reduction of \>1.2 points, or a score ≤5.1 with reduction of \>0.6 to ≤1.2 points, were assessed as having a 'moderate' response. Participants with a score \>5.1 with reduction of \>0.6 to ≤1.2 points, or any score with reduction ≤0.6 points, were assessed as nonresponders with response recorded as 'none.'
Time frame: Weeks 16 and 32
Percentage of Participants Achieving a Response According to EULAR Criteria at Weeks 20, 24, 28, and 32 Among Participants Treated With 8 Courses of Tocilizumab
Response was determined using EULAR criteria based upon DAS28 absolute scores at the assessment visit and the DAS28 reduction from Baseline. Participants with a score ≤3.2 and reduction of \>1.2 points were assessed as having a 'good' response. Participants with a score \>3.2 with reduction of \>1.2 points, or a score ≤5.1 with reduction of \>0.6 to ≤1.2 points, were assessed as having a 'moderate' response. Participants with a score \>5.1 with reduction of \>0.6 to ≤1.2 points, or any score with reduction ≤0.6 points, were assessed as nonresponders with response recorded as 'none.'
Time frame: Baseline and Weeks 20, 24, 28, and 32
Percentage of Participants Achieving a Response According to American College of Rheumatology (ACR) Criteria at Weeks 4, 8, 12, and 16
Response was determined using ACR criteria based upon assessment of 66 joints for swelling and 68 joints for tenderness; joints were classified dichotomously as swollen or not swollen and tender or not tender. Respectively, these assessments were used to generate a swollen joint count (SJC) ranging from 0 to 66 swollen joints and a tender joint count (TJC) ranging from 0 to 68 tender joints. Response was defined as a reduction from Baseline of at least 20% for one of the following: VAS scores for patient-reported pain, patient global assessment of disease activity, or physician global assessment of disease activity, Health Assessment Questionnaire Disability Index (HAQ-DI), or C-reactive protein (CRP); plus a reduction in individual SJC and TJC of 20% (ACR20), 50% (ACR50), or 70% (ACR70). VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.'
Time frame: Baseline and Weeks 4, 8, 12, and 16
Percentage of Participants Achieving a Response According to ACR Criteria at Week 32 Compared to Week 16 Among Nonresponding Participants Treated With Rituximab
Response was determined using ACR criteria based upon assessment of 66 joints for swelling and 68 joints for tenderness; joints were classified dichotomously as swollen or not swollen and tender or not tender. Respectively, these assessments were used to generate an SJC ranging from 0 to 66 swollen joints and a TJC ranging from 0 to 68 tender joints. Response was defined as a reduction from the reference visit (Week 16) of at least 20% for one of the following: VAS scores for patient-reported pain, patient global assessment of disease activity, or physician global assessment of disease activity, HAQ-DI, or CRP; plus a reduction in individual SJC and TJC of 20% (ACR20), 50% (ACR50), or 70% (ACR70). VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.'
Time frame: Weeks 16 and 32
Percentage of Participants Achieving a Response According to ACR Criteria at Weeks 20, 24, 28, and 32 Among Participants Treated With 8 Courses of Tocilizumab
Response was determined using ACR criteria based upon assessment of 66 joints for swelling and 68 joints for tenderness; joints were classified dichotomously as swollen or not swollen and tender or not tender. Respectively, these assessments were used to generate an SJC ranging from 0 to 66 swollen joints and a TJC ranging from 0 to 68 tender joints. Response was defined as a reduction from Baseline of at least 20% for one of the following: VAS scores for patient-reported pain, patient global assessment of disease activity, or physician global assessment of disease activity, HAQ-DI, or CRP; plus a reduction in individual SJC and TJC of 20% (ACR20), 50% (ACR50), or 70% (ACR70). VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.'
Time frame: Baseline and Weeks 20, 24, 28, and 32
Change From Baseline in Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) Scores at Weeks 4, 8, 12, and 16
The CDAI was calculated as \[SJC + TJC + VAS patient global assessment of disease activity + VAS physician global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity. The SDAI was determined by adding CRP level to the CDAI score. Scores ranged from 0 to 86, with higher scores also indicating increased disease activity. A reduction in either score at the assessment visit reflects improvement in disease.
Time frame: Baseline and Weeks 4, 8, 12, and 16
Change From Week 16 to 32 in CDAI and SDAI Scores Among Nonresponding Participants Treated With Rituximab
The CDAI was calculated as \[SJC + TJC + VAS patient global assessment of disease activity + VAS physician global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity. The SDAI was determined by adding CRP level to the CDAI score. Scores ranged from 0 to 86, with higher scores also indicating increased disease activity. A reduction in either score at the assessment visit reflects improvement in disease.
Time frame: Weeks 16 and 32
Change From Baseline in CDAI and SDAI Scores at Weeks 20, 24, 28, and 32 Among Participants Treated With 8 Courses of Tocilizumab
The CDAI was calculated as \[SJC + TJC + VAS patient global assessment of disease activity + VAS physician global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity. The SDAI was determined by adding CRP level to the CDAI score. Scores ranged from 0 to 86, with higher scores also indicating increased disease activity. A reduction in either score at the assessment visit reflects improvement in disease.
Time frame: Baseline and Weeks 20, 24, 28, and 32
Change From Baseline in Hemoglobin at Weeks 4, 8, 12, and 16
Blood samples for laboratory assessments, including hemoglobin level, were collected prior to each dose of study medication. The mean hemoglobin level was determined at Baseline and for assessment visits by averaging the observed hemoglobin level among all participants providing evaluable blood samples. Change from Baseline was calculated as \[mean hemoglobin at the assessment visit minus mean hemoglobin at Baseline\] and expressed in grams per liter (g/L).
Time frame: Baseline and Weeks 4, 8, 12, and 16
Change From Baseline in CRP at Weeks 4, 8, 12, and 16
Blood samples for laboratory assessments, including CRP level, were collected prior to each dose of study medication. The mean CRP level was determined at Baseline and for assessment visits by averaging the observed CRP level among all participants providing evaluable blood samples. Change from Baseline was calculated as \[mean CRP at the assessment visit minus mean CRP at Baseline\] and expressed in milligrams per deciliter (mg/dL).
Time frame: Baseline and Weeks 4, 8, 12, and 16
Change From Baseline in ESR at Weeks 4, 8, 12, and 16
Blood samples for laboratory assessments, including ESR, were collected prior to each dose of study medication. The mean ESR was determined at Baseline and for assessment visits by averaging the observed ESR among all participants providing evaluable blood samples. Change from Baseline was calculated as \[mean ESR at the assessment visit minus mean ESR at Baseline\] and expressed in millimeters per hour (mm/h).
Time frame: Baseline and Weeks 4, 8, 12, and 16
Change in Hemoglobin From Week 16 to 32 Among Nonresponding Participants Treated With Rituximab
Blood samples for laboratory assessments, including hemoglobin level, were collected prior to each dose of study medication. The mean hemoglobin level was determined at Baseline and for assessment visits by averaging the observed hemoglobin level among all participants providing evaluable blood samples. Change was calculated as \[mean hemoglobin at Week 32 minus mean hemoglobin at Week 16\] and expressed in g/L.
Time frame: Weeks 16 and 32
Change in CRP From Week 16 to 32 Among Nonresponding Participants Treated With Rituximab
Blood samples for laboratory assessments, including CRP level, were collected prior to each dose of study medication. The mean CRP level was determined at Baseline and for assessment visits by averaging the observed CRP level among all participants providing evaluable blood samples. Change was calculated as \[mean CRP at Week 32 minus mean CRP at Week 16\] and expressed in mg/dL.
Time frame: Weeks 16 and 32
Change in ESR From Week 16 to 32 Among Nonresponding Participants Treated With Rituximab
Blood samples for laboratory assessments, including ESR, were collected prior to each dose of study medication. The mean ESR was determined at Baseline and for assessment visits by averaging the observed ESR among all participants providing evaluable blood samples. Change was calculated as \[mean ESR at Week 32 minus mean ESR at Week 16\] and expressed in mm/h.
Time frame: Weeks 16 and 32
Change From Baseline in Hemoglobin at Weeks 20, 24, 28, and 32 Among Participants Treated With 8 Courses of Tocilizumab
Blood samples for laboratory assessments, including hemoglobin level, were collected prior to each dose of study medication. The mean hemoglobin level was determined at Baseline and for assessment visits by averaging the observed hemoglobin level among all participants providing evaluable blood samples. Change from Baseline was calculated as \[mean hemoglobin at the assessment visit minus mean hemoglobin at Baseline\] and expressed in g/L.
Time frame: Baseline and Weeks 20, 24, 28, and 32
Change From Baseline in CRP at Weeks 20, 24, 28, and 32 Among Participants Treated With 8 Courses of Tocilizumab
Blood samples for laboratory assessments, including CRP level, were collected prior to each dose of study medication. The mean CRP level was determined at Baseline and for assessment visits by averaging the observed CRP level among all participants providing evaluable blood samples. Change from Baseline was calculated as \[mean CRP at the assessment visit minus mean CRP at Baseline\] and expressed in mg/dL.
Time frame: Baseline and Weeks 20, 24, 28, and 32
Change From Baseline in ESR at Weeks 20, 24, 28, and 32 Among Participants Treated With 8 Courses of Tocilizumab
Blood samples for laboratory assessments, including ESR, were collected prior to each dose of study medication. The mean ESR was determined at Baseline and for assessment visits by averaging the observed ESR among all participants providing evaluable blood samples. Change from Baseline was calculated as \[mean ESR at the assessment visit minus mean ESR at Baseline\] and expressed in mm/h.
Time frame: Baseline and Weeks 20, 24, 28, and 32
Percentage of Participants Withdrawing From the Study for Insufficient Therapeutic Response
Study discontinuation was documented by reason for each participant prematurely withdrawing from the study. The percentage of participants was calculated as the number withdrawing for insufficient therapeutic response divided by the total number of participants who began treatment.
Time frame: Baseline to Week 16
Percentage of B-Cells at Baseline by B-Cell Subpopulation Among Participants With Early Remission
Blood samples were collected to analyze total B-cell panel via immunophenotyping. Subpopulations were as follows: transitional (cluster of differentiation \[CD\] 19-positive, immunoglobulin (Ig) D-positive, CD38 medium, CD10-positive); naive (CD19-positive, IgD-positive, CD38 medium, CD27-negative); pre-switch memory (CD19-positive, CD27-positive, IgD-positive); post-switch memory (CD19-positive, CD27-positive, IgD-negative); IgG-positive class-switched (CD19-positive, IgG-positive); IgA-positive class-switched (CD19-positive, IgA-positive); double-negative memory (CD19-positive, IgD-negative, CD27-negative); and plasmablasts (CD19-positive, IgD-negative, CD38 high, CD27 high). Naive B-cell compartment was defined as the sum of transitional and naive B-cells. The sum of memory B-cell subsets with or without double-negative B-cells was also determined.
Time frame: Baseline
Percentage of B-Cells at Baseline by B-Cell Subpopulation Among Participants Treated With 8 Courses of Tocilizumab
Blood samples were collected to analyze total B-cell panel via immunophenotyping. Subpopulations were as follows: transitional (cluster of differentiation \[CD\] 19-positive, immunoglobulin (Ig) D-positive, CD38 medium, CD10-positive); naive (CD19-positive, IgD-positive, CD38 medium, CD27-negative); pre-switch memory (CD19-positive, CD27-positive, IgD-positive); post-switch memory (CD19-positive, CD27-positive, IgD-negative); IgG-positive class-switched (CD19-positive, IgG-positive); IgA-positive class-switched (CD19-positive, IgA-positive); double-negative memory (CD19-positive, IgD-negative, CD27-negative); and plasmablasts (CD19-positive, IgD-negative, CD38 high, CD27 high). Naive B-cell compartment was defined as the sum of transitional and naive B-cells. The sum of memory B-cell subsets with or without double-negative B-cells was also determined.
Time frame: Baseline
Percentage of B-Cells at Baseline by B-Cell Subpopulation Among Nonresponding Participants Treated With Rituximab
Blood samples were collected to analyze total B-cell panel via immunophenotyping. Subpopulations were as follows: transitional (cluster of differentiation \[CD\] 19-positive, immunoglobulin (Ig) D-positive, CD38 medium, CD10-positive); naive (CD19-positive, IgD-positive, CD38 medium, CD27-negative); pre-switch memory (CD19-positive, CD27-positive, IgD-positive); post-switch memory (CD19-positive, CD27-positive, IgD-negative); IgG-positive class-switched (CD19-positive, IgG-positive); IgA-positive class-switched (CD19-positive, IgA-positive); double-negative memory (CD19-positive, IgD-negative, CD27-negative); and plasmablasts (CD19-positive, IgD-negative, CD38 high, CD27 high). Naive B-cell compartment was defined as the sum of transitional and naive B-cells. The sum of memory B-cell subsets with or without double-negative B-cells was also determined.
Time frame: Baseline
Spearman's Rank Correlation Coefficient Between Percentage of B-Cells at Baseline and Difference in DAS28 Scores Between Baseline and Week 16 Among Participants With Early Remission
Blood samples were collected to analyze total B-cell panel via immunophenotyping. Subpopulations were as follows: transitional, naïve, pre-switch memory, post-switch memory, IgG-positive class-switched, IgA-positive class-switched, double-negative memory, and plasmablasts. Naive B-cell compartment was defined as the sum of transitional and naive B-cells. The sum of memory B-cell subsets with or without double-negative B-cells was also determined. Extent of disease response, using change from Baseline to Week 16 in DAS28 score, was correlated to the percentage of B-cells within each subpopulation at Baseline. Correlation is indicated by a correlation coefficient (r) \>0.2, with greater values indicating a stronger correlation.
Time frame: Baseline and Week 16
Spearman's Rank Correlation Coefficient Between Percentage of B-Cells at Baseline and Difference in DAS28 Scores Between Baseline and Weeks 16, 24, and 32 Among Participants Treated With 8 Courses of Tocilizumab
Blood samples were collected to analyze total B-cell panel via immunophenotyping. Subpopulations were as follows: transitional, naïve, pre-switch memory, post-switch memory, IgG-positive class-switched, IgA-positive class-switched, double-negative memory, and plasmablasts. Naive B-cell compartment was defined as the sum of transitional and naive B-cells. The sum of memory B-cell subsets with or without double-negative B-cells was also determined. Extent of disease response, using change from Baseline in DAS28 score, was correlated to the percentage of B-cells within each subpopulation at Baseline. Correlation is indicated by a correlation coefficient (r) \>0.2, with greater values indicating a stronger correlation.
Time frame: Baseline and Weeks 16, 24, and 32
Spearman's Rank Correlation Coefficient Between Percentage of B-Cells at Baseline and Difference in DAS28 Scores Between Baseline and Weeks 16, 32, 40, 48, and 66 Among Nonresponding Participants Treated With Rituximab
Blood samples were collected to analyze total B-cell panel via immunophenotyping. Subpopulations were as follows: transitional, naïve, pre-switch memory, post-switch memory, IgG-positive class-switched, IgA-positive class-switched, double-negative memory, and plasmablasts. Naive B-cell compartment was defined as the sum of transitional and naive B-cells. The sum of memory B-cell subsets with or without double-negative B-cells was also determined. Extent of disease response, using change from Baseline in DAS28 score, was correlated to the percentage of B-cells within each subpopulation at Baseline. Correlation is indicated by a correlation coefficient (r) \>0.2, with greater values indicating a stronger correlation.
Time frame: Baseline and Weeks 16, 32, 40, 48, and 66
Mean Number of Work Days Missed Per Week
Work days missed were documented by reason (either rheumatoid arthritis \[RA\] or other reasons) for each participant over the preceding 7-day period. The mean number of work days missed was calculated by averaging the number of days missed per week among all participants.
Time frame: Baseline and Week 16
Quality of Life as Assessed Using Short Form 36 (SF-36)
The SF-36 evaluates participant-rated quality of life using 8 domains: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, and mental health. The score for each section is the average of the individual question scores, which are scaled from 0 to 100, with higher scores indicating better functioning. The mean score at each timepoint was determined by averaging the scores among all participants.
Time frame: Baseline and Week 16
Change From Baseline in Quality of Life as Assessed Using SF-36 at Week 16
The SF-36 evaluates participant-rated quality of life using 8 domains: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, and mental health. The score for each section is the average of the individual question scores, which are scaled from 0 to 100, with higher scores indicating better functioning. The mean score at each timepoint was determined by averaging the scores among all participants, and the change in each domain score was calculated as \[mean score at Week 16 minus mean score at Baseline\].
Time frame: Baseline and Week 16
Change From Week 16 to 32 in Quality of Life as Assessed Using SF-36 Scores Among Participants Treated With 8 Courses of Tocilizumab
The SF-36 evaluates participant-rated quality of life using 8 domains: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, and mental health. The score for each section is the average of the individual question scores, which are scaled from 0 to 100, with higher scores indicating better functioning. The mean score at each timepoint was determined by averaging the scores among all participants, and the change in each domain score was calculated as \[mean score at Week 32 minus mean score at Week 16\].
Time frame: Weeks 16 and 32
Change From Week 16 to 32 in Quality of Life as Assessed Using SF-36 Scores Among Nonresponding Participants Treated With Rituximab
The SF-36 evaluates participant-rated quality of life using 8 domains: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, and mental health. The score for each section is the average of the individual question scores, which are scaled from 0 to 100, with higher scores indicating better functioning. The mean score at each timepoint was determined by averaging the scores among all participants, and the change in each domain score was calculated as \[mean score at Week 32 minus mean score at Week 16\].
Time frame: Weeks 16 and 32
Quality of Life as Assessed Using HAQ-DI
The HAQ-DI evaluates participant-reported quality of life using 8 categories: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and other common activities such as running errands and performing household chores. Each category contains multiple questions, which are answered using a 4-point scale from 0 to 3. The overall index score is taken as an average of the individual item responses and may range from 0 to 3, where higher scores indicate more difficulty in daily living activities. The mean index score at each timepoint was determined by averaging the scores among all participants.
Time frame: Baseline and Week 16
Change From Baseline in Quality of Life as Assessed Using HAQ-DI at Week 16
The HAQ-DI evaluates participant-reported quality of life using 8 categories: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and other common activities such as running errands and performing household chores. Each category contains multiple questions, which are answered using a 4-point scale from 0 to 3. The overall index score is taken as an average of the individual item responses and may range from 0 to 3, where higher scores indicate more difficulty in daily living activities. The mean index score at each timepoint was determined by averaging the scores among all participants, and the change in score was calculated as \[mean score at Week 16 minus mean score at Baseline\].
Time frame: Baseline and Week 16
Change From Week 16 to 32 in Quality of Life as Assessed Using HAQ-DI Among Participants Treated With 8 Courses of Tocilizumab
The HAQ-DI evaluates participant-reported quality of life using 8 categories: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and other common activities such as running errands and performing household chores. Each category contains multiple questions, which are answered using a 4-point scale from 0 to 3. The overall index score is taken as an average of the individual item responses and may range from 0 to 3, where higher scores indicate more difficulty in daily living activities. The mean index score at each timepoint was determined by averaging the scores among all participants, and the change in score was calculated as \[mean score at Week 32 minus the mean score at Week 16\].
Time frame: Weeks 16 and 32
Change From Week 16 to 32 in Quality of Life as Assessed Using HAQ-DI Among Nonresponding Participants Treated With Rituximab
The HAQ-DI evaluates participant-reported quality of life using 8 categories: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and other common activities such as running errands and performing household chores. Each category contains multiple questions, which are answered using a 4-point scale from 0 to 3. The overall index score is taken as an average of the individual item responses and may range from 0 to 3, where higher scores indicate more difficulty in daily living activities. The mean index score at each timepoint was determined by averaging the scores among all participants, and the change in score was calculated as \[mean score at Week 32 minus the mean score at Week 16\].
Time frame: Weeks 16 and 32
Percentage of Participants Achieving a Response According to HAQ-DI Criteria
The HAQ-DI evaluates participant-reported quality of life using 8 categories: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and other common activities such as running errands and performing household chores. Each category contains multiple questions, which are answered using a 4-point scale from 0 to 3. The overall index score is taken as an average of the individual item responses and may range from 0 to 3, where higher scores indicate more difficulty in daily living activities. Response was defined as a change in index score \>0.22 from Baseline to Week 16.
Time frame: Baseline and Week 16
Quality of Life as Assessed Using Functional Assessment of Chronic Illness Therapy (FACIT)
The FACIT-F evaluates quality of life using 5 categories: physical well-being (PWB), social/family well-being (SWB), emotional well-being (EWB), functional well-being (FWB), and fatigue (FS). Participants answer each item on a 5-point scale from 0 to 4. The total score is the sum of individual responses across all 5 categories and may range from 0 to 160. The FACIT-General (FACIT-G; range 0 to 108) is the sum of scores for PWB, SWB, EWB, and FWB; the FACIT-Fatigue (FACIT-F) trial outcome index (TOI; range 0 to 108) is the sum of scores for PWB, FWB, and FS; and the FACIT-F fatigue (range 0 to 52) is the sum of scores for the FS only. For derivations of the FACIT-F reported here, higher scores indicate better quality of life. The mean score at each timepoint was determined by averaging scores among all participants.
Time frame: Baseline and Week 16
Change From Baseline in Quality of Life as Assessed Using FACIT at Week 16
The FACIT-F evaluates quality of life using 5 categories: PWB, SWB, EWB, FWB, and FS. Participants answer each item on a 5-point scale from 0 to 4. The total score is the sum of individual responses across all 5 categories and may range from 0 to 160. The FACIT-G (range 0 to 108) is the sum of scores for PWB, SWB, EWB, and FWB; the FACIT-F TOI (range 0 to 108) is the sum of scores for PWB, FWB, and FS; and the FACIT-F fatigue (range 0 to 52) is the sum of scores for the FS only. For derivations of the FACIT-F reported here, higher scores indicate better quality of life. The mean score at each timepoint was determined by averaging scores among all participants, and the change in score was calculated as \[mean score at Week 16 minus mean score at Baseline\].
Time frame: Baseline and Week 16
Change From Week 16 to 32 in Quality of Life as Assessed Using FACIT Among Participants Treated With 8 Courses of Tocilizumab
The FACIT-F evaluates quality of life using 5 categories: PWB, SWB, EWB, FWB, and FS. Participants answer each item on a 5-point scale from 0 to 4. The total score is the sum of individual responses across all 5 categories and may range from 0 to 160. The FACIT-G (range 0 to 108) is the sum of scores for PWB, SWB, EWB, and FWB; the FACIT-F TOI (range 0 to 108) is the sum of scores for PWB, FWB, and FS; and the FACIT-F fatigue (range 0 to 52) is the sum of scores for the FS only. For derivations of the FACIT-F reported here, higher scores indicate better quality of life. The mean score at each timepoint was determined by averaging scores among all participants, and the change in score was calculated as \[mean score at Week 32 minus mean score at Week 16\].
Time frame: Weeks 16 and 32
Change From Week 16 to 32 in Quality of Life as Assessed Using FACIT Among Nonresponding Participants Treated With Rituximab
The FACIT-F evaluates quality of life using 5 categories: PWB, SWB, EWB, FWB, and FS. Participants answer each item on a 5-point scale from 0 to 4. The total score is the sum of individual responses across all 5 categories and may range from 0 to 160. The FACIT-G (range 0 to 108) is the sum of scores for PWB, SWB, EWB, and FWB; the FACIT-F TOI (range 0 to 108) is the sum of scores for PWB, FWB, and FS; and the FACIT-F fatigue (range 0 to 52) is the sum of scores for the FS only. For derivations of the FACIT-F reported here, higher scores indicate better quality of life. The mean score at each timepoint was determined by averaging scores among all participants, and the change in score was calculated as \[mean score at Week 32 minus mean score at Week 16\].
Time frame: Weeks 16 and 32
| Milestone | Tocilizumab (TCZ)/TCZ or TCZ/Rituximab (RTX) |
|---|---|
| Started | 519 |
| Completed week 16 | 463 |
| Completed week 32 (tcz/tcz) | 200 |
| Completed week 32 (tcz/rtx) | 26 |
| Completed week 66 (tcz/rtx) | 25 |
| Completed | 448 |
| Not completed | 71 |
| Withdrew: Adverse event | 34 |
| Withdrew: Death | 1 |
| Withdrew: Lack of efficacy | 1 |
| Withdrew: Lost to follow-up | 4 |
| Withdrew: Protocol violation | 6 |
| Withdrew: Withdrawal by subject | 15 |
| Withdrew: Administrative problem | 2 |
| Withdrew: Other | 8 |
The DAS28 was calculated as \[0.28 times (x) the square root of number of swollen joints\] plus (+) \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of erythrocyte sedimentation rate (ESR)\] + \[0.014 x Visual Analog Scale (VAS) patient global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity. Remission was defined as a DAS28 score \<2.6 at the assessment visit.
| percentage of participants | TCZ/TCZ or TCZ/RTX |
|---|---|
| Percentage of Participants Achieving Remission at Week 16 According to DAS28 | 42.8 (38.5 to 47.2) |
The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x VAS patient global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity. Remission was defined as a DAS28 score \<2.6 at the assessment visit.
| percentage of participants | TCZ/TCZ or TCZ/RTX |
|---|---|
| Week 4 | 21.6 (18.1 to 25.4) |
| Week 8 | 40.1 (35.8 to 44.4) |
| Week 12 | 43.2 (38.9 to 47.5) |
The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x VAS patient global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity. Remission was defined as a DAS28 score \<2.6 at the assessment visit.
| percentage of participants | TCZ/TCZ or TCZ/RTX |
|---|---|
| Week 16 | 1.4 (0.3 to 4.1) |
| Week 20 | 41.3 (34.6 to 48.2) |
| Week 24 | 51.2 (44.3 to 58.1) |
| Week 28 | 55.9 (48.9 to 62.6) |
The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x VAS patient global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity. Remission was defined as a DAS28 score \<2.6 at the assessment visit.
| percentage of participants | TCZ/TCZ or TCZ/RTX |
|---|---|
| Percentage of Participants Achieving Remission According to DAS28 at Week 32 Among Participants Treated With 8 Courses of Tocilizumab | 54.9 (48.0 to 61.7) |
The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x VAS patient global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity. Remission was defined as a DAS28 score \<2.6 at the assessment visit.
| percentage of participants | TCZ/TCZ or TCZ/RTX |
|---|---|
| Percentage of Participants Achieving Remission According to DAS28 at Week 32 Among Nonresponding Participants Treated With Rituximab | 14.8 (4.2 to 33.7) |
The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x the patient global assessment of disease activity using a VAS\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity. LDAS was defined as a DAS28 score \<3.2 at the assessment visit.
| percentage of participants | TCZ/TCZ or TCZ/RTX |
|---|---|
| Percentage of Participants Achieving Low Disease Activity Score (LDAS) According to DAS28 | 68.8 (64.6 to 72.8) |
The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x the patient global assessment of disease activity using a VAS\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity. LDAS was defined as a DAS28 score \<3.2 at the assessment visit.
| percentage of participants | TCZ/TCZ or TCZ/RTX |
|---|---|
| Percentage of Participants Achieving LDAS According to DAS28 Among Among Nonresponding Participants Treated With Rituximab | 33.3 (16.5 to 54.0) |
The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x VAS patient global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity. Reductions \>1.2 points from Baseline to the assessment visit were considered clinically relevant.
| percentage of participants | TCZ/TCZ or TCZ/RTX |
|---|---|
| Percentage of Participants Achieving a Clinically Relevant Reduction From Baseline in DAS28 at Week 16 | 86.1 (82.9 to 89.0) |
The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x VAS patient global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity. Reductions \>1.2 points from Baseline to the assessment visit were considered clinically relevant.
| percentage of participants | TCZ/TCZ or TCZ/RTX |
|---|---|
| Week 4 | 74.6 (70.6 to 78.3) |
| Week 8 | 81.5 (77.9 to 84.8) |
| Week 12 | 83.4 (79.9 to 86.5) |
The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x VAS patient global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity. Reductions \>1.2 points from the reference visit (Week 16) to the assessment visit were considered clinically relevant.
| percentage of participants | TCZ/TCZ or TCZ/RTX |
|---|---|
| Percentage of Participants Achieving a Clinically Relevant Reduction in DAS28 From Week 16 to Week 32 Among Nonresponding Participants Treated With Rituximab | 37.0 (19.4 to 57.6) |
The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x VAS patient global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity.
| units on a scale | TCZ/TCZ or TCZ/RTX |
|---|---|
| Baseline (n=516) | 5.7 ± 1.0 |
| Week 4 (n=508) | 3.6 ± 1.3 |
| Week 8 (n=491) | 3.0 ± 1.4 |
| Week 12 (n=483) | 2.8 ± 1.4 |
| Week 16 (n=485) | 2.6 ± 1.3 |
The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x VAS patient global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity.
| units on a scale | TCZ/TCZ or TCZ/RTX |
|---|---|
| Baseline (n=213) | 6.0 ± 0.9 |
| Week 4 (n=213) | 4.0 ± 1.2 |
| Week 8 (n=205) | 3.4 ± 1.2 |
| Week 12 (n=207) | 3.3 ± 1.1 |
| Week 16 (n=213) | 3.3 ± 0.6 |
| Week 20 (n=206) | 2.8 ± 1.0 |
| Week 24 (n=197) | 2.6 ± 1.1 |
| Week 28 (n=200) | 2.4 ± 1.1 |
| Week 32 (n=193) | 2.5 ± 1.2 |
The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x VAS patient global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity.
| units on a scale | TCZ/TCZ or TCZ/RTX |
|---|---|
| Baseline (n=27) | 5.7 ± 1.0 |
| Week 4 (n=27) | 4.5 ± 1.2 |
| Week 8 (n=26) | 4.2 ± 1.5 |
| Week 12 (n=27) | 4.8 ± 1.6 |
| Week 16 (n=27) | 5.1 ± 1.2 |
| Week 24 (n=26) | 4.6 ± 1.4 |
| Week 32 (n=26) | 4.0 ± 1.5 |
The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x VAS patient global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' DAS28 scores ranged from 0 to 10, with higher scores indicating increased disease activity.
| units on a scale | TCZ/TCZ or TCZ/RTX |
|---|---|
| Week 40 (n=26) | 3.9 ± 1.5 |
| Week 48 (n=25) | 3.9 ± 1.2 |
| Week 56 (n=22) | 4.1 ± 1.8 |
| Week 66 (n=25) | 3.9 ± 1.5 |
Response was determined using EULAR criteria based upon DAS28 absolute scores at the assessment visit and the DAS28 reduction from Baseline. Participants with a score ≤3.2 and reduction of \>1.2 points were assessed as having a 'good' response. Participants with a score \>3.2 with reduction of \>1.2 points, or a score ≤5.1 with reduction of \>0.6 to ≤1.2 points, were assessed as having a 'moderate' response. Participants with a score \>5.1 with reduction of \>0.6 to ≤1.2 points, or any score with reduction ≤0.6 points, were assessed as nonresponders with response recorded as 'none.'
| percentage of participants | TCZ/TCZ or TCZ/RTX |
|---|---|
| Week 4, Good | 36.0 (31.9 to 40.3) |
| Week 4, Moderate | 47.8 (43.4 to 52.2) |
| Week 4, None | 16.2 (13.1 to 19.6) |
| Week 8, Good | 56.1 (51.7 to 60.4) |
| Week 8, Moderate | 30.6 (26.7 to 34.8) |
| Week 8, None | 13.3 (10.5 to 16.5) |
| Week 12, Good | 61.1 (56.7 to 65.3) |
| Week 12, Moderate | 25.6 (21.9 to 29.6) |
| Week 12, None | 13.3 (10.5 to 16.5) |
| Week 16, Good | 68.2 (64.0 to 72.2) |
| Week 16, Moderate | 20.2 (16.9 to 23.9) |
| Week 16, None | 11.6 (8.9 to 14.6) |
Response was determined using EULAR criteria based upon DAS28 absolute scores at the assessment visit and the DAS28 reduction from the reference visit (Week 16). Participants with a score ≤3.2 and reduction of \>1.2 points were assessed as having a 'good' response. Participants with a score \>3.2 with reduction of \>1.2 points, or a score ≤5.1 with reduction of \>0.6 to ≤1.2 points, were assessed as having a 'moderate' response. Participants with a score \>5.1 with reduction of \>0.6 to ≤1.2 points, or any score with reduction ≤0.6 points, were assessed as nonresponders with response recorded as 'none.'
| percentage of participants | TCZ/TCZ or TCZ/RTX |
|---|---|
| Good | 25.9 (11.1 to 46.3) |
| Moderate | 29.6 (13.8 to 50.2) |
| None | 44.4 (25.5 to 64.7) |
Response was determined using EULAR criteria based upon DAS28 absolute scores at the assessment visit and the DAS28 reduction from Baseline. Participants with a score ≤3.2 and reduction of \>1.2 points were assessed as having a 'good' response. Participants with a score \>3.2 with reduction of \>1.2 points, or a score ≤5.1 with reduction of \>0.6 to ≤1.2 points, were assessed as having a 'moderate' response. Participants with a score \>5.1 with reduction of \>0.6 to ≤1.2 points, or any score with reduction ≤0.6 points, were assessed as nonresponders with response recorded as 'none.'
| percentage of participants | TCZ/TCZ or TCZ/RTX |
|---|---|
| Week 20, Good | 65.3 (58.5 to 71.6) |
| Week 20, Moderate | 30.0 (24.0 to 36.7) |
| Week 20, None | 4.7 (2.3 to 8.5) |
| Week 24, Good | 68.1 (61.4 to 74.3) |
| Week 24, Moderate | 23.9 (18.4 to 30.3) |
| Week 24, None | 8.0 (4.7 to 12.5) |
| Week 28, Good | 72.8 (66.3 to 78.6) |
| Week 28, Moderate | 19.2 (14.2 to 25.2) |
| Week 28, None | 8.0 (4.7 to 12.5) |
| Week 32, Good | 66.7 (59.9 to 73.0) |
| Week 32, Moderate | 20.7 (15.4 to 26.7) |
| Week 32, None | 12.7 (8.5 to 17.9) |
Response was determined using ACR criteria based upon assessment of 66 joints for swelling and 68 joints for tenderness; joints were classified dichotomously as swollen or not swollen and tender or not tender. Respectively, these assessments were used to generate a swollen joint count (SJC) ranging from 0 to 66 swollen joints and a tender joint count (TJC) ranging from 0 to 68 tender joints. Response was defined as a reduction from Baseline of at least 20% for one of the following: VAS scores for patient-reported pain, patient global assessment of disease activity, or physician global assessment of disease activity, Health Assessment Questionnaire Disability Index (HAQ-DI), or C-reactive protein (CRP); plus a reduction in individual SJC and TJC of 20% (ACR20), 50% (ACR50), or 70% (ACR70). VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.'
| percentage of participants | TCZ/TCZ or TCZ/RTX |
|---|---|
| Week 4, ACR20 | 39.1 (34.9 to 43.5) |
| Week 4, ACR50 | 15.0 (12.1 to 18.4) |
| Week 4, ACR70 | 5.8 (3.9 to 8.1) |
| Week 8, ACR20 | 61.1 (56.7 to 65.3) |
| Week 8, ACR50 | 33.5 (29.5 to 37.8) |
| Week 8, ACR70 | 15.2 (12.2 to 18.6) |
| Week 12, ACR20 | 64.0 (59.7 to 68.1) |
| Week 12, ACR50 | 42.8 (38.5 to 47.2) |
| Week 12, ACR70 | 20.2 (16.9 to 23.9) |
| Week 16, ACR20 | 67.1 (62.8 to 71.1) |
| Week 16, ACR50 | 45.7 (41.3 to 50.1) |
| Week 16, ACR70 | 24.5 (20.8 to 28.4) |
Response was determined using ACR criteria based upon assessment of 66 joints for swelling and 68 joints for tenderness; joints were classified dichotomously as swollen or not swollen and tender or not tender. Respectively, these assessments were used to generate an SJC ranging from 0 to 66 swollen joints and a TJC ranging from 0 to 68 tender joints. Response was defined as a reduction from the reference visit (Week 16) of at least 20% for one of the following: VAS scores for patient-reported pain, patient global assessment of disease activity, or physician global assessment of disease activity, HAQ-DI, or CRP; plus a reduction in individual SJC and TJC of 20% (ACR20), 50% (ACR50), or 70% (ACR70). VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.'
| percentage of participants | TCZ/TCZ or TCZ/RTX |
|---|---|
| ACR20 | 40.7 (22.4 to 61.2) |
| ACR50 | 33.3 (16.5 to 54.0) |
| ACR70 | 22.2 (8.6 to 42.3) |
Response was determined using ACR criteria based upon assessment of 66 joints for swelling and 68 joints for tenderness; joints were classified dichotomously as swollen or not swollen and tender or not tender. Respectively, these assessments were used to generate an SJC ranging from 0 to 66 swollen joints and a TJC ranging from 0 to 68 tender joints. Response was defined as a reduction from Baseline of at least 20% for one of the following: VAS scores for patient-reported pain, patient global assessment of disease activity, or physician global assessment of disease activity, HAQ-DI, or CRP; plus a reduction in individual SJC and TJC of 20% (ACR20), 50% (ACR50), or 70% (ACR70). VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.'
| percentage of participants | TCZ/TCZ or TCZ/RTX |
|---|---|
| Week 20, ACR20 | 74.2 (67.8 to 79.9) |
| Week 20, ACR50 | 45.1 (38.3 to 52.0) |
| Week 20, ACR70 | 21.1 (15.8 to 27.2) |
| Week 24, ACR20 | 72.8 (66.3 to 78.6) |
| Week 24, ACR50 | 49.8 (42.9 to 56.7) |
| Week 24, ACR70 | 21.6 (16.3 to 27.7) |
| Week 28, ACR20 | 73.2 (66.8 to 79.1) |
| Week 28, ACR50 | 53.1 (46.1 to 59.9) |
| Week 28, ACR70 | 30.5 (24.4 to 37.2) |
| Week 32, ACR20 | 75.6 (69.2 to 81.2) |
| Week 32, ACR50 | 54.9 (48.0 to 61.7) |
| Week 32, ACR70 | 34.3 (27.9 to 41.1) |
The CDAI was calculated as \[SJC + TJC + VAS patient global assessment of disease activity + VAS physician global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity. The SDAI was determined by adding CRP level to the CDAI score. Scores ranged from 0 to 86, with higher scores also indicating increased disease activity. A reduction in either score at the assessment visit reflects improvement in disease.
| units on a scale | TCZ/TCZ or TCZ/RTX |
|---|---|
| CDAI, Week 4 (n=509) | -10.9 ± 10.2 |
| CDAI, Week 8 (n=497) | -16.5 ± 11.1 |
| CDAI, Week 12 (n=486) | -18.3 ± 11.5 |
| CDAI, Week 16 (n=485) | -19.4 ± 11.5 |
| SDAI, Week 4 (n=496) | -12.3 ± 10.6 |
| SDAI, Week 8 (n=489) | -17.9 ± 11.5 |
| SDAI, Week 12 (n=474) | -19.7 ± 11.9 |
| SDAI, Week 16 (n=471) | -20.7 ± 12.2 |
The CDAI was calculated as \[SJC + TJC + VAS patient global assessment of disease activity + VAS physician global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity. The SDAI was determined by adding CRP level to the CDAI score. Scores ranged from 0 to 86, with higher scores also indicating increased disease activity. A reduction in either score at the assessment visit reflects improvement in disease.
| units on a scale | TCZ/TCZ or TCZ/RTX |
|---|---|
| CDAI (n=25) | -14.2 ± 12.0 |
| SDAI (n=24) | -14.0 ± 12.5 |
The CDAI was calculated as \[SJC + TJC + VAS patient global assessment of disease activity + VAS physician global assessment of disease activity\]. VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity.' CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity. The SDAI was determined by adding CRP level to the CDAI score. Scores ranged from 0 to 86, with higher scores also indicating increased disease activity. A reduction in either score at the assessment visit reflects improvement in disease.
| units on a scale | TCZ/TCZ or TCZ/RTX |
|---|---|
| CDAI, Week 20 (n=208) | -21.7 ± 11.7 |
| CDAI, Week 24 (n=199) | -22.8 ± 11.4 |
| CDAI, Week 28 (n=200) | -24.6 ± 12.5 |
| CDAI, Week 32 (n=194) | -24.0 ± 13.4 |
| SDAI, Week 20 (n=200) | -22.9 ± 12.5 |
| SDAI, Week 24 (n=190) | -24.3 ± 12.1 |
| SDAI, Week 28 (n=195) | -25.9 ± 13.2 |
| SDAI, Week 32 (n=189) | -25.2 ± 14.0 |
Blood samples for laboratory assessments, including hemoglobin level, were collected prior to each dose of study medication. The mean hemoglobin level was determined at Baseline and for assessment visits by averaging the observed hemoglobin level among all participants providing evaluable blood samples. Change from Baseline was calculated as \[mean hemoglobin at the assessment visit minus mean hemoglobin at Baseline\] and expressed in grams per liter (g/L).
| g/L | TCZ/TCZ or TCZ/RTX |
|---|---|
| Week 4 (n=509) | 4.9 ± 7.2 |
| Week 8 (n=496) | 6.4 ± 8.8 |
| Week 12 (n=483) | 6.9 ± 9.1 |
| Week 16 (n=477) | 7.5 ± 9.1 |
Blood samples for laboratory assessments, including CRP level, were collected prior to each dose of study medication. The mean CRP level was determined at Baseline and for assessment visits by averaging the observed CRP level among all participants providing evaluable blood samples. Change from Baseline was calculated as \[mean CRP at the assessment visit minus mean CRP at Baseline\] and expressed in milligrams per deciliter (mg/dL).
| mg/dL | TCZ/TCZ or TCZ/RTX |
|---|---|
| Week 4 (n=497) | -1.4 ± 1.9 |
| Week 8 (n=492) | -1.4 ± 1.9 |
| Week 12 (n=476) | -1.4 ± 1.9 |
| Week 16 (n=471) | -1.3 ± 1.9 |
Blood samples for laboratory assessments, including ESR, were collected prior to each dose of study medication. The mean ESR was determined at Baseline and for assessment visits by averaging the observed ESR among all participants providing evaluable blood samples. Change from Baseline was calculated as \[mean ESR at the assessment visit minus mean ESR at Baseline\] and expressed in millimeters per hour (mm/h).
| mm/h | TCZ/TCZ or TCZ/RTX |
|---|---|
| Week 4 (n=507) | -25.2 ± 18.1 |
| Week 8 (n=494) | -26.6 ± 18.9 |
| Week 12 (n=484) | -26.3 ± 19.1 |
| Week 16 (n=484) | -27.5 ± 18.7 |
Blood samples for laboratory assessments, including hemoglobin level, were collected prior to each dose of study medication. The mean hemoglobin level was determined at Baseline and for assessment visits by averaging the observed hemoglobin level among all participants providing evaluable blood samples. Change was calculated as \[mean hemoglobin at Week 32 minus mean hemoglobin at Week 16\] and expressed in g/L.
| g/L | TCZ/TCZ or TCZ/RTX |
|---|---|
| Change in Hemoglobin From Week 16 to 32 Among Nonresponding Participants Treated With Rituximab | -2.0 ± 8.3 |
Blood samples for laboratory assessments, including CRP level, were collected prior to each dose of study medication. The mean CRP level was determined at Baseline and for assessment visits by averaging the observed CRP level among all participants providing evaluable blood samples. Change was calculated as \[mean CRP at Week 32 minus mean CRP at Week 16\] and expressed in mg/dL.
| mg/dL | TCZ/TCZ or TCZ/RTX |
|---|---|
| Change in CRP From Week 16 to 32 Among Nonresponding Participants Treated With Rituximab | 0.7 ± 1.7 |
Blood samples for laboratory assessments, including ESR, were collected prior to each dose of study medication. The mean ESR was determined at Baseline and for assessment visits by averaging the observed ESR among all participants providing evaluable blood samples. Change was calculated as \[mean ESR at Week 32 minus mean ESR at Week 16\] and expressed in mm/h.
| mm/h | TCZ/TCZ or TCZ/RTX |
|---|---|
| Change in ESR From Week 16 to 32 Among Nonresponding Participants Treated With Rituximab | 11.5 ± 17.9 |
Blood samples for laboratory assessments, including hemoglobin level, were collected prior to each dose of study medication. The mean hemoglobin level was determined at Baseline and for assessment visits by averaging the observed hemoglobin level among all participants providing evaluable blood samples. Change from Baseline was calculated as \[mean hemoglobin at the assessment visit minus mean hemoglobin at Baseline\] and expressed in g/L.
| g/L | TCZ/TCZ or TCZ/RTX |
|---|---|
| Week 20 (n=207) | 5.5 ± 9.0 |
| Week 24 (n=198) | 6.6 ± 9.4 |
| Week 28 (n=197) | 6.9 ± 9.5 |
| Week 32 (n=197) | 8.3 ± 10.4 |
Blood samples for laboratory assessments, including CRP level, were collected prior to each dose of study medication. The mean CRP level was determined at Baseline and for assessment visits by averaging the observed CRP level among all participants providing evaluable blood samples. Change from Baseline was calculated as \[mean CRP at the assessment visit minus mean CRP at Baseline\] and expressed in mg/dL.
| mg/dL | TCZ/TCZ or TCZ/RTX |
|---|---|
| Week 20 (n=200) | -1.3 ± 1.9 |
| Week 24 (n=191) | -1.4 ± 1.9 |
| Week 28 (n=195) | -1.3 ± 1.9 |
| Week 32 (n=192) | -1.3 ± 1.9 |
Blood samples for laboratory assessments, including ESR, were collected prior to each dose of study medication. The mean ESR was determined at Baseline and for assessment visits by averaging the observed ESR among all participants providing evaluable blood samples. Change from Baseline was calculated as \[mean ESR at the assessment visit minus mean ESR at Baseline\] and expressed in mm/h.
| mm/h | TCZ/TCZ or TCZ/RTX |
|---|---|
| Week 20 (n=206) | -28.6 ± 17.6 |
| Week 24 (n=197) | -29.4 ± 18.0 |
| Week 28 (n=200) | -29.4 ± 18.1 |
| Week 32 (n=196) | -28.6 ± 20.2 |
Study discontinuation was documented by reason for each participant prematurely withdrawing from the study. The percentage of participants was calculated as the number withdrawing for insufficient therapeutic response divided by the total number of participants who began treatment.
| percentage of participants | TCZ/TCZ or TCZ/RTX |
|---|---|
| Percentage of Participants Withdrawing From the Study for Insufficient Therapeutic Response | 0.2 (0.0 to 1.1) |
Blood samples were collected to analyze total B-cell panel via immunophenotyping. Subpopulations were as follows: transitional (cluster of differentiation \[CD\] 19-positive, immunoglobulin (Ig) D-positive, CD38 medium, CD10-positive); naive (CD19-positive, IgD-positive, CD38 medium, CD27-negative); pre-switch memory (CD19-positive, CD27-positive, IgD-positive); post-switch memory (CD19-positive, CD27-positive, IgD-negative); IgG-positive class-switched (CD19-positive, IgG-positive); IgA-positive class-switched (CD19-positive, IgA-positive); double-negative memory (CD19-positive, IgD-negative, CD27-negative); and plasmablasts (CD19-positive, IgD-negative, CD38 high, CD27 high). Naive B-cell compartment was defined as the sum of transitional and naive B-cells. The sum of memory B-cell subsets with or without double-negative B-cells was also determined.
| percentage of B-cells | TCZ/TCZ or TCZ/RTX |
|---|---|
| Naive B-cell compartment (n=196) | 61.1 (5.3 to 102.9) |
| Transitional B-cells (n=196) | 1.4 (0.1 to 18.8) |
| Naive B-cells (n=196) | 58.1 (3.4 to 94.2) |
| Memory including double-negative (n=46) | 56.4 (20.2 to 103.5) |
| Memory excluding double-negative (n=194) | 46.5 (5.6 to 125.8) |
| Pre-switch memory B-cells (n=196) | 11.1 (1.3 to 73.6) |
| Post-switch memory B-cells (n=196) | 16.4 (0.8 to 58.1) |
| IgG-positive class-switched B-cells (n=195) | 9.9 (0.3 to 42) |
| IgA-positive class-switched B-cells (n=194) | 7.4 (0.7 to 35.6) |
| Double-negative B-cells (n=46) | 6.1 (2.5 to 16.3) |
| Plasmablasts (n=196) | 0.3 (0 to 19.9) |
Blood samples were collected to analyze total B-cell panel via immunophenotyping. Subpopulations were as follows: transitional (cluster of differentiation \[CD\] 19-positive, immunoglobulin (Ig) D-positive, CD38 medium, CD10-positive); naive (CD19-positive, IgD-positive, CD38 medium, CD27-negative); pre-switch memory (CD19-positive, CD27-positive, IgD-positive); post-switch memory (CD19-positive, CD27-positive, IgD-negative); IgG-positive class-switched (CD19-positive, IgG-positive); IgA-positive class-switched (CD19-positive, IgA-positive); double-negative memory (CD19-positive, IgD-negative, CD27-negative); and plasmablasts (CD19-positive, IgD-negative, CD38 high, CD27 high). Naive B-cell compartment was defined as the sum of transitional and naive B-cells. The sum of memory B-cell subsets with or without double-negative B-cells was also determined.
| percentage of B-cells | TCZ/TCZ or TCZ/RTX |
|---|---|
| Naive B-cell compartment (n=197) | 57.1 (5.6 to 91.2) |
| Transitional B-cells (n=197) | 1.3 (0.0 to 13.4) |
| Naive B-cells (n=197) | 55.5 (4.7 to 87.1) |
| Memory including double-negative (n=57) | 63.2 (18.8 to 113.7) |
| Memory excluding double-negative (n=196) | 49.7 (10.9 to 120.1) |
| Pre-switch memory B-cells (n=197) | 11.6 (0.9 to 74.1) |
| Post-switch memory B-cells (n=197) | 17.2 (2.8 to 52.7) |
| IgG-positive class-switched B-cells (n=196) | 10 (0.2 to 38.4) |
| IgA-positive class-switched B-cells (n=196) | 8.0 (1.4 to 34.4) |
| Double-negative B-cells (n=57) | 6.6 (1.2 to 19.1) |
| Plasmablasts (n=197) | 0.3 (0 to 7.6) |
Blood samples were collected to analyze total B-cell panel via immunophenotyping. Subpopulations were as follows: transitional (cluster of differentiation \[CD\] 19-positive, immunoglobulin (Ig) D-positive, CD38 medium, CD10-positive); naive (CD19-positive, IgD-positive, CD38 medium, CD27-negative); pre-switch memory (CD19-positive, CD27-positive, IgD-positive); post-switch memory (CD19-positive, CD27-positive, IgD-negative); IgG-positive class-switched (CD19-positive, IgG-positive); IgA-positive class-switched (CD19-positive, IgA-positive); double-negative memory (CD19-positive, IgD-negative, CD27-negative); and plasmablasts (CD19-positive, IgD-negative, CD38 high, CD27 high). Naive B-cell compartment was defined as the sum of transitional and naive B-cells. The sum of memory B-cell subsets with or without double-negative B-cells was also determined.
| percentage of B-cells | TCZ/TCZ or TCZ/RTX |
|---|---|
| Naive B-cell compartment (n=25) | 65.9 (9.8 to 85.0) |
| Transitional B-cells (n=25) | 1.6 (0.2 to 7.0) |
| Naive B-cells (n=25) | 61.9 (5.8 to 83.4) |
| Memory including double-negative (n=4) | 45.1 (37.1 to 86.7) |
| Memory excluding double-negative (n=25) | 41.5 (21.6 to 139.6) |
| Pre-switch memory B-cells (n=25) | 9.1 (2.4 to 36.2) |
| Post-switch memory B-cells (n=25) | 16.1 (6.9 to 64.1) |
| IgG-positive class-switched B-cells (n=25) | 8.7 (5.0 to 32.7) |
| IgA-positive class-switched B-cells (n=25) | 7.7 (3.4 to 29.3) |
| Double-negative B-cells (n=4) | 7.5 (5.9 to 9.1) |
| Plasmablasts (n=25) | 0.3 (0.0 to 3.2) |
Blood samples were collected to analyze total B-cell panel via immunophenotyping. Subpopulations were as follows: transitional, naïve, pre-switch memory, post-switch memory, IgG-positive class-switched, IgA-positive class-switched, double-negative memory, and plasmablasts. Naive B-cell compartment was defined as the sum of transitional and naive B-cells. The sum of memory B-cell subsets with or without double-negative B-cells was also determined. Extent of disease response, using change from Baseline to Week 16 in DAS28 score, was correlated to the percentage of B-cells within each subpopulation at Baseline. Correlation is indicated by a correlation coefficient (r) \>0.2, with greater values indicating a stronger correlation.
| coefficient | TCZ/TCZ or TCZ/RTX |
|---|---|
| Naive B-cell compartment (n=192) | -0.02258 |
| Transitional B-cells (n=192) | -0.00949 |
| Naive B-cells (n=192) | -0.01920 |
| Memory B-cells (n=62) | -0.03148 |
| Pre-switch memory B-cells (n=192) | 0.03221 |
| Post-switch memory B-cells (n=192) | 0.05419 |
| IgG-positive class-switched B-cells (n=192) | 0.08864 |
| IgA-positive class-switched B-cells (n=192) | 0.01041 |
| Double-negative B-cells (n=62) | -0.02134 |
| Plasmablasts (n=192) | 0.00397 |
Blood samples were collected to analyze total B-cell panel via immunophenotyping. Subpopulations were as follows: transitional, naïve, pre-switch memory, post-switch memory, IgG-positive class-switched, IgA-positive class-switched, double-negative memory, and plasmablasts. Naive B-cell compartment was defined as the sum of transitional and naive B-cells. The sum of memory B-cell subsets with or without double-negative B-cells was also determined. Extent of disease response, using change from Baseline in DAS28 score, was correlated to the percentage of B-cells within each subpopulation at Baseline. Correlation is indicated by a correlation coefficient (r) \>0.2, with greater values indicating a stronger correlation.
| coefficient | TCZ/TCZ or TCZ/RTX |
|---|---|
| Week 16, Naive B-cell compartment (n=199) | 0.00007 |
| Week 16, Transitional B-cells (n=199) | -0.06529 |
| Week 16, Naive B-cells (n=199) | 0.02334 |
| Week 16, Memory B-cells (n=75) | 0.03478 |
| Week 16, Pre-switch memory B-cells (n=199) | -0.01889 |
| Week 16, Post-switch memory B-cells (n=199) | -0.04161 |
| Week 16, IgG-positive class-switched (n=199) | -0.06235 |
| Week 16, IgA-positive class-switched (n=199) | -0.06492 |
| Week 16, Double-negative B-cells (n=75) | -0.04352 |
| Week 16, Plasmablasts (n=199) | -0.13161 |
| Week 24, Naive B-cell compartment (n=162) | -0.18469 |
| Week 24, Transitional B-cells (n=162) | -0.21966 |
| Week 24, Naive B-cells (n=162) | -0.15683 |
| Week 24, Memory B-cells (n=76) | 0.15135 |
| Week 24, Pre-switch memory B-cells (n=162) | 0.08074 |
| Week 24, Post-switch memory B-cells (n=162) | 0.10798 |
| Week 24, IgG-positive class-switched (n=161) | 0.10752 |
| Week 24, IgA-positive class-switched (n=162) | 0.11023 |
| Week 24, Double-negative B-cells (n=76) | 0.05609 |
| Week 24, Plasmablasts (n=162) | 0.07468 |
| Week 32, Naive B-cell compartment (n=179) | -0.12635 |
| Week 32, Transitional B-cells (n=179) | -0.09234 |
| Week 32, Naive B-cells (n=179) | -0.11114 |
| Week 32, Memory B-cells (n=88) | 0.05361 |
| Week 32, Pre-switch memory B-cells (n=179) | 0.12265 |
| Week 32, Post-switch memory B-cells (n=179) | 0.05867 |
| Week 32, IgG-positive class-switched (n=181) | 0.06381 |
| Week 32, IgA-positive class-switched (n=181) | 0.06036 |
| Week 32, Double-negative B-cells (n=90) | -0.06310 |
| Week 32, Plasmablasts (n=179) | 0.02205 |
Blood samples were collected to analyze total B-cell panel via immunophenotyping. Subpopulations were as follows: transitional, naïve, pre-switch memory, post-switch memory, IgG-positive class-switched, IgA-positive class-switched, double-negative memory, and plasmablasts. Naive B-cell compartment was defined as the sum of transitional and naive B-cells. The sum of memory B-cell subsets with or without double-negative B-cells was also determined. Extent of disease response, using change from Baseline in DAS28 score, was correlated to the percentage of B-cells within each subpopulation at Baseline. Correlation is indicated by a correlation coefficient (r) \>0.2, with greater values indicating a stronger correlation.
| coefficient | TCZ/TCZ or TCZ/RTX |
|---|---|
| Week 16, Naive B-cell compartment (n=24) | 0.09611 |
| Week 16, Transitional B-cells (n=24) | 0.08571 |
| Week 16, Naive B-cells (n=24) | 0.00870 |
| Week 16, Memory B-cells (n=6) | -0.60000 |
| Week 16, Pre-switch memory B-cells (n=24) | -0.15217 |
| Week 16, Post-switch memory B-cells (n=24) | -0.04004 |
| Week 16, IgG-positive class-switched (n=24) | -0.07528 |
| Week 16, IgA-positive class-switched (n=24) | 0.27049 |
| Week 16, Double-negative B-cells (n=6) | -0.14286 |
| Week 16, Plasmablasts (n=24) | 0.13232 |
| Week 32, Naive B-cell compartment (n=0) | NA |
| Week 32, Transitional B-cells (n=0) | NA |
| Week 32, Naive B-cells (n=0) | NA |
| Week 32, Memory B-cells (n=0) | NA |
| Week 32, Pre-switch memory B-cells (n=0) | NA |
| Week 32, Post-switch memory B-cells (n=0) | NA |
| Week 32, IgG-positive class-switched (n=0) | NA |
| Week 32, IgA-positive class-switched (n=0) | NA |
| Week 32, Double-negative B-cells (n=0) | NA |
| Week 32, Plasmablasts (n=0) | NA |
| Week 40, Naive B-cell compartment (n=2) | 1.00000 |
| Week 40, Transitional B-cells (n=2) | -1.00000 |
| Week 40, Naive B-cells (n=2) | 1.00000 |
| Week 40, Memory B-cells (n=0) | NA |
| Week 40, Pre-switch memory B-cells (n=2) | 1.00000 |
| Week 40, Post-switch memory B-cells (n=2) | 1.00000 |
| Week 40, IgG-positive class-switched (n=2) | 1.00000 |
| Week 40, IgA-positive class-switched (n=2) | 1.00000 |
| Week 40, Double-negative B-cells (n=0) | NA |
| Week 40, Plasmablasts (n=2) | 1.00000 |
| Week 48, Naive B-cell compartment (n=5) | 0.30000 |
| Week 48, Transitional B-cells (n=5) | -0.60000 |
| Week 48, Naive B-cells (n=5) | 0.30000 |
| Week 48, Memory B-cells (n=1) | NA |
| Week 48, Pre-switch memory B-cells (n=5) | 0.60000 |
| Week 48, Post-switch memory B-cells (n=5) | 0.20000 |
| Week 48, IgG-positive class-switched (n=5) | 0.20000 |
| Week 48, IgA-positive class-switched (n=5) | 0.50000 |
| Week 48, Double-negative B-cells (n=1) | NA |
| Week 48, Plasmablasts (n=5) | 0.10000 |
| Week 66, Naive B-cell compartment (n=10) | 0.12727 |
| Week 66, Transitional B-cells (n=10) | -0.03030 |
| Week 66, Naive B-cells (n=10) | 0.04242 |
| Week 66, Memory B-cells (n=3) | 1.00000 |
| Week 66, Pre-switch memory B-cells (n=10) | -0.03030 |
| Week 66, Post-switch memory B-cells (n=10) | 0.16364 |
| Week 66, IgG-positive class-switched (n=10) | 0.07295 |
| Week 66, IgA-positive class-switched (n=10) | 0.12805 |
| Week 66, Double-negative B-cells (n=3) | 1.00000 |
| Week 66, Plasmablasts (n=10) | 0.30909 |
Work days missed were documented by reason (either rheumatoid arthritis \[RA\] or other reasons) for each participant over the preceding 7-day period. The mean number of work days missed was calculated by averaging the number of days missed per week among all participants.
| days | TCZ/TCZ or TCZ/RTX |
|---|---|
| Due to RA, Baseline (n=241) | 1.03 ± 2.30 |
| Due to RA, Week 16 (n=221) | 0.39 ± 1.51 |
| Due to other reasons, Baseline (n=233) | 0.14 ± 0.87 |
| Due to other reasons, Week 16 (n=222) | 0.32 ± 1.26 |
The SF-36 evaluates participant-rated quality of life using 8 domains: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, and mental health. The score for each section is the average of the individual question scores, which are scaled from 0 to 100, with higher scores indicating better functioning. The mean score at each timepoint was determined by averaging the scores among all participants.
| units on a scale | TCZ/TCZ or TCZ/RTX |
|---|---|
| Physical functioning, Baseline (n=511) | 49.6 ± 23.7 |
| Physical functioning, Week 16 (n=473) | 64.1 ± 25.5 |
| Role (physical), Baseline (n=508) | 12.9 ± 18.1 |
| Role (physical), Week 16 (n=472) | 29.9 ± 21.4 |
| Bodily pain, Baseline (n=512) | 31.3 ± 18.2 |
| Bodily pain, Week 16 (n=474) | 55.3 ± 17.8 |
| General health, Baseline (n=504) | 43.6 ± 16.7 |
| General health, Week 16 (n=468) | 54.3 ± 18.3 |
| Vitality, Baseline (n=512) | 44.0 ± 19.7 |
| Vitality, Week 16 (n=474) | 58.1 ± 20.4 |
| Social functioning, Baseline (n=507) | 68.1 ± 24.8 |
| Social functioning, Week 16 (n=464) | 80.1 ± 21.6 |
| Role (emotional), Baseline (n=505) | 55.9 ± 45.0 |
| Role (emotional), Week 16 (n=472) | 70.9 ± 42.1 |
| Mental health, Baseline (n=513) | 63.5 ± 18.7 |
| Mental health, Week 16 (n=474) | 72.3 ± 17.9 |
The SF-36 evaluates participant-rated quality of life using 8 domains: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, and mental health. The score for each section is the average of the individual question scores, which are scaled from 0 to 100, with higher scores indicating better functioning. The mean score at each timepoint was determined by averaging the scores among all participants, and the change in each domain score was calculated as \[mean score at Week 16 minus mean score at Baseline\].
| units on a scale | TCZ/TCZ or TCZ/RTX |
|---|---|
| Physical functioning (n=466) | 14.3 ± 21.8 |
| Role (physical) (n=461) | 17.0 ± 22.0 |
| Bodily pain (n=470) | 23.9 ± 21.1 |
| General health (n=454) | 10.4 ± 18.5 |
| Vitality (n=468) | 13.9 ± 19.3 |
| Social functioning (n=456) | 12.0 ± 23.8 |
| Role (emotional) (n=459) | 14.7 ± 46.1 |
| Mental health (n=468) | 8.7 ± 16.8 |
The SF-36 evaluates participant-rated quality of life using 8 domains: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, and mental health. The score for each section is the average of the individual question scores, which are scaled from 0 to 100, with higher scores indicating better functioning. The mean score at each timepoint was determined by averaging the scores among all participants, and the change in each domain score was calculated as \[mean score at Week 32 minus mean score at Week 16\].
| units on a scale | TCZ/TCZ or TCZ/RTX |
|---|---|
| Physical functioning (n=188) | 3.6 ± 16.6 |
| Role (physical) (n=187) | 2.0 ± 20.6 |
| Bodily pain (n=188) | 3.2 ± 16.5 |
| General health (n=184) | 2.6 ± 14.3 |
| Vitality (n=186) | 2.7 ± 14.2 |
| Social functioning (n=184) | -0.3 ± 19.6 |
| Role (emotional) (n=184) | 5.5 ± 42.3 |
| Mental health (n=186) | 0.7 ± 15.3 |
The SF-36 evaluates participant-rated quality of life using 8 domains: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, and mental health. The score for each section is the average of the individual question scores, which are scaled from 0 to 100, with higher scores indicating better functioning. The mean score at each timepoint was determined by averaging the scores among all participants, and the change in each domain score was calculated as \[mean score at Week 32 minus mean score at Week 16\].
| units on a scale | TCZ/TCZ or TCZ/RTX |
|---|---|
| Physical functioning (n=26) | 2.5 ± 20.0 |
| Role (physical) (n=24) | -1.0 ± 21.5 |
| Bodily pain (n=26) | 10.6 ± 20.8 |
| General health (n=24) | 5.2 ± 18.1 |
| Vitality (n=26) | 1.0 ± 9.3 |
| Social functioning (n=24) | -3.1 ± 17.4 |
| Role (emotional) (n=24) | 2.8 ± 35.3 |
| Mental health (n=26) | 3.4 ± 10.7 |
The HAQ-DI evaluates participant-reported quality of life using 8 categories: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and other common activities such as running errands and performing household chores. Each category contains multiple questions, which are answered using a 4-point scale from 0 to 3. The overall index score is taken as an average of the individual item responses and may range from 0 to 3, where higher scores indicate more difficulty in daily living activities. The mean index score at each timepoint was determined by averaging the scores among all participants.
| units on a scale | TCZ/TCZ or TCZ/RTX |
|---|---|
| Baseline (n=513) | 1.24 ± 0.67 |
| Week 16 (n=472) | 0.75 ± 0.67 |
The HAQ-DI evaluates participant-reported quality of life using 8 categories: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and other common activities such as running errands and performing household chores. Each category contains multiple questions, which are answered using a 4-point scale from 0 to 3. The overall index score is taken as an average of the individual item responses and may range from 0 to 3, where higher scores indicate more difficulty in daily living activities. The mean index score at each timepoint was determined by averaging the scores among all participants, and the change in score was calculated as \[mean score at Week 16 minus mean score at Baseline\].
| units on a scale | TCZ/TCZ or TCZ/RTX |
|---|---|
| Change From Baseline in Quality of Life as Assessed Using HAQ-DI at Week 16 | -0.48 ± 0.58 |
The HAQ-DI evaluates participant-reported quality of life using 8 categories: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and other common activities such as running errands and performing household chores. Each category contains multiple questions, which are answered using a 4-point scale from 0 to 3. The overall index score is taken as an average of the individual item responses and may range from 0 to 3, where higher scores indicate more difficulty in daily living activities. The mean index score at each timepoint was determined by averaging the scores among all participants, and the change in score was calculated as \[mean score at Week 32 minus the mean score at Week 16\].
| units on a scale | TCZ/TCZ or TCZ/RTX |
|---|---|
| Change From Week 16 to 32 in Quality of Life as Assessed Using HAQ-DI Among Participants Treated With 8 Courses of Tocilizumab | -0.06 ± 0.34 |
The HAQ-DI evaluates participant-reported quality of life using 8 categories: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and other common activities such as running errands and performing household chores. Each category contains multiple questions, which are answered using a 4-point scale from 0 to 3. The overall index score is taken as an average of the individual item responses and may range from 0 to 3, where higher scores indicate more difficulty in daily living activities. The mean index score at each timepoint was determined by averaging the scores among all participants, and the change in score was calculated as \[mean score at Week 32 minus the mean score at Week 16\].
| units on a scale | TCZ/TCZ or TCZ/RTX |
|---|---|
| Change From Week 16 to 32 in Quality of Life as Assessed Using HAQ-DI Among Nonresponding Participants Treated With Rituximab | -0.10 ± 0.39 |
The HAQ-DI evaluates participant-reported quality of life using 8 categories: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and other common activities such as running errands and performing household chores. Each category contains multiple questions, which are answered using a 4-point scale from 0 to 3. The overall index score is taken as an average of the individual item responses and may range from 0 to 3, where higher scores indicate more difficulty in daily living activities. Response was defined as a change in index score \>0.22 from Baseline to Week 16.
| percentage of participants | TCZ/TCZ or TCZ/RTX |
|---|---|
| Percentage of Participants Achieving a Response According to HAQ-DI Criteria | 61.1 |
The FACIT-F evaluates quality of life using 5 categories: physical well-being (PWB), social/family well-being (SWB), emotional well-being (EWB), functional well-being (FWB), and fatigue (FS). Participants answer each item on a 5-point scale from 0 to 4. The total score is the sum of individual responses across all 5 categories and may range from 0 to 160. The FACIT-General (FACIT-G; range 0 to 108) is the sum of scores for PWB, SWB, EWB, and FWB; the FACIT-Fatigue (FACIT-F) trial outcome index (TOI; range 0 to 108) is the sum of scores for PWB, FWB, and FS; and the FACIT-F fatigue (range 0 to 52) is the sum of scores for the FS only. For derivations of the FACIT-F reported here, higher scores indicate better quality of life. The mean score at each timepoint was determined by averaging scores among all participants.
| units on a scale | TCZ/TCZ or TCZ/RTX |
|---|---|
| FACIT-F TOI, Baseline (n=498) | 66.2 ± 20.6 |
| FACIT-F TOI, Week 16 (n=460) | 80.8 ± 19.3 |
| FACIT-G total, Baseline (n=498) | 71.1 ± 15.7 |
| FACIT-G total, Week 16 (n=462) | 82.6 ± 15.9 |
| FACIT-F total, Baseline (n=494) | 103.8 ± 25.5 |
| FACIT-F total, Week 16 (n=458) | 121.9 ± 25.3 |
| FACIT-F fatigue, Baseline (n=510) | 32.7 ± 11.6 |
| FACIT-F fatigue, Week 16 (n=475) | 39.2 ± 10.6 |
The FACIT-F evaluates quality of life using 5 categories: PWB, SWB, EWB, FWB, and FS. Participants answer each item on a 5-point scale from 0 to 4. The total score is the sum of individual responses across all 5 categories and may range from 0 to 160. The FACIT-G (range 0 to 108) is the sum of scores for PWB, SWB, EWB, and FWB; the FACIT-F TOI (range 0 to 108) is the sum of scores for PWB, FWB, and FS; and the FACIT-F fatigue (range 0 to 52) is the sum of scores for the FS only. For derivations of the FACIT-F reported here, higher scores indicate better quality of life. The mean score at each timepoint was determined by averaging scores among all participants, and the change in score was calculated as \[mean score at Week 16 minus mean score at Baseline\].
| units on a scale | TCZ/TCZ or TCZ/RTX |
|---|---|
| FACIT-F TOI (n=445) | 14.2 ± 17.9 |
| FACIT-G total (n=445) | 10.8 ± 13.6 |
| FACIT-F total (n=439) | 17.5 ± 21.8 |
| FACIT-F fatigue (n=467) | 6.6 ± 9.9 |
The FACIT-F evaluates quality of life using 5 categories: PWB, SWB, EWB, FWB, and FS. Participants answer each item on a 5-point scale from 0 to 4. The total score is the sum of individual responses across all 5 categories and may range from 0 to 160. The FACIT-G (range 0 to 108) is the sum of scores for PWB, SWB, EWB, and FWB; the FACIT-F TOI (range 0 to 108) is the sum of scores for PWB, FWB, and FS; and the FACIT-F fatigue (range 0 to 52) is the sum of scores for the FS only. For derivations of the FACIT-F reported here, higher scores indicate better quality of life. The mean score at each timepoint was determined by averaging scores among all participants, and the change in score was calculated as \[mean score at Week 32 minus mean score at Week 16\].
| units on a scale | TCZ/TCZ or TCZ/RTX |
|---|---|
| FACIT-F TOI (n=172) | 1.7 ± 12.9 |
| FACIT-G total (n=174) | 1.1 ± 9.2 |
| FACIT-F total (n=170) | 2.0 ± 15.1 |
| FACIT-F fatigue (n=186) | 0.8 ± 7.4 |
The FACIT-F evaluates quality of life using 5 categories: PWB, SWB, EWB, FWB, and FS. Participants answer each item on a 5-point scale from 0 to 4. The total score is the sum of individual responses across all 5 categories and may range from 0 to 160. The FACIT-G (range 0 to 108) is the sum of scores for PWB, SWB, EWB, and FWB; the FACIT-F TOI (range 0 to 108) is the sum of scores for PWB, FWB, and FS; and the FACIT-F fatigue (range 0 to 52) is the sum of scores for the FS only. For derivations of the FACIT-F reported here, higher scores indicate better quality of life. The mean score at each timepoint was determined by averaging scores among all participants, and the change in score was calculated as \[mean score at Week 32 minus mean score at Week 16\].
| units on a scale | TCZ/TCZ or TCZ/RTX |
|---|---|
| FACIT-F TOI | 2.9 ± 9.8 |
| FACIT-G total | 3.0 ± 8.3 |
| FACIT-F total | 4.4 ± 12.5 |
| FACIT-F fatigue | 1.4 ± 5.8 |
Collected over Up to 66 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TCZ/TCZ or TCZ/RTX | — | 54/519 (10.4%) | 104/519 (20%) |
| Event | TCZ/TCZ or TCZ/RTX |
|---|---|
| BronchitisInfections and infestations | 3/519 |
| BursitisMusculoskeletal and connective tissue disorders | 3/519 |
| Abdominal painGastrointestinal disorders | 2/519 |
| HypersensitivityImmune system disorders | 2/519 |
| DiverticulitisInfections and infestations | 2/519 |
| PneumoniaInfections and infestations | 2/519 |
| FallInjury, poisoning and procedural complications | 2/519 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 2/519 |
| LeukopeniaBlood and lymphatic system disorders | 1/519 |
| NeutropeniaBlood and lymphatic system disorders | 1/519 |
| Event | TCZ/TCZ or TCZ/RTX |
|---|---|
| NasopharyngitisInfections and infestations | 77/519 |
| HypertensionVascular disorders | 30/519 |
Main Intent-to-Treat (ITT) Population: All participants who received at least one dose of TCZ.
| Age, Continuous(years) | TCZ/TCZ or TCZ/RTX |
|---|---|
| Mean | 55.7 ± 11.9 |
| Sex: Female, Male(Participants) | TCZ/TCZ or TCZ/RTX |
|---|---|
| Female | 352 |
| Male | 167 |
The record gives a start of Mar 2011, a primary completion of Feb 2014 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2015, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tocilizumab